Uremic toxins and oral adsorbents

Area of Science:

• Nephrology
• Gastroenterology
• Toxicology

Background:

• Uremic toxins contribute to disorders in end-stage renal disease (ESRD) patients.
• Some toxins originate from colonic bacterial metabolites, posing challenges for dialysis removal.
• Oral adsorbents offer a strategy to mitigate uremic toxin accumulation by interfering with gut absorption.

Purpose of the Study:

• To review the role and potential of oral adsorbents in managing uremic syndrome.
• To discuss specific agents like AST-120 and sevelamer hydrochloride.
• To highlight the challenges in removing protein-bound uremic toxins in vivo.

Main Methods:

• Review of existing literature on oral adsorbents and uremic toxins.
• Discussion of AST-120's mechanism of adsorbing uremic retention solutes.
• Analysis of sevelamer hydrochloride's effects, including in vitro vs. in vivo findings.

Main Results:

• AST-120 demonstrates potential for clinical benefit by adsorbing gastrointestinal uremic solutes.
• Sevelamer hydrochloride binds compounds beyond phosphate, with pleiotropic effects.
• In vitro studies show sevelamer's effect on indoxyl sulfate and p-cresol, but in vivo data is limited for protein-bound toxins.

Conclusions:

• Oral adsorbents represent a significant therapeutic approach for uremic syndrome.
• Targeting gut-generated toxins is a key strategy in managing ESRD complications.
• Further in vivo validation is needed for certain oral adsorbents' efficacy on specific uremic toxins.